2020 annual financial data
SAB Biotherapeutics 2020 Operating cash flow margin
Direct answer
Operating cash flow margin was 18.11%.
Operating income was 20,557,000 USD and net income was 20,118,000 USD.
Operating cash flow was 10,004,795 USD.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 55,238,000 USD
- Operating income
- 20,557,000 USD
- Net income
- 20,118,000 USD
- Operating cash flow
- 10,004,795 USD